+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 19 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of oral brepocitinib in adults with lichen planopilaris, a condition affecting the scalp. This Phase 23 trial aims to understand how well this medication works compared to a placebo in treating active and symptomatic lichen planopilaris. The study is sponsored by Priovant Therapeutics, Inc. and uses a randomized, double-blind design to ensure reliable results. Participants are randomly assigned to receive either oral brepocitinib or a placebo. The study is conducted in parallel groups, with neither the participants nor the researchers knowing who receives the active drug or placebo. The treatment period lasts 24 weeks, during which the participants take the assigned oral medication. The main goal is to measure improvement in the Investigator Global Assessment IGA score by Week 24. Throughout the study, participants will be regularly monitored for safety and symptom changes. Researchers will assess the proportion of participants who achieve significant improvement in their IGA scores at Week 24 and track changes in symptom severity using a numerical rating scale. The total study duration extends until July 2029, allowing for thorough evaluation of treatment effects and safety over time.

Age: 18Years +All GendersPhase 2Phase 3
61 locations
S

Actively Recruiting

Researchers are evaluating the investigational drug SPY072 in adults aged 18 to 75 with moderate to severe hidradenitis suppurativa HS who are also receiving advanced standard of care treatment. This Phase 2, multicenter, randomized, double-blind study aims to assess whether SPY072 can improve symptoms of HS compared to placebo while continuing standard treatment. The study will also monitor safety and how long any treatment effects last. Participants will be randomly assigned to receive either SPY072 or a matching placebo, both given as subcutaneous injections, alongside bimekizumab, an advanced standard of care medication. The treatment period lasts 16 weeks, after which participants enter a follow-up phase to evaluate ongoing safety and durability of response. During the study, participants will undergo regular assessments including clinical evaluations of HS lesions and response to treatment. Researchers will measure outcomes such as the percentage of participants achieving a significant clinical response at Week 16. Safety monitoring will continue up to 52 weeks, and participants progress will be closely tracked throughout the treatment and follow-up periods, which may last until the study ends in mid-2028.

Age: 18Years - 75YearsAll GendersPhase 2
34 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of THB335 in adults with chronic spontaneous urticaria CSU who continue to experience hives and itching despite treatment with a second-generation H1 antihistamine. This Phase 2, randomized, double-blind, placebo-controlled study aims to compare two doses of THB335 against a placebo. The study is designed for adults aged 18 to 85 who remain symptomatic despite standard care. Participants will be randomly assigned to receive either a higher dose or a lower dose of THB335, or a matching placebo, taken orally once daily for 12 weeks. All participants will continue their stable antihistamine treatment during this period. The study includes a Screening Period of up to 4 weeks before treatment, followed by a 12-week Treatment Period, and then a 4-week Follow-Up Period. During the trial, participants will complete daily electronic diaries to track symptoms such as hives and itching, and attend scheduled study visits for assessments. Researchers will measure changes in weekly Urticaria Activity Score UAS7 and other related scores from baseline to Week 12. Safety will be monitored through the recording of adverse events, vital signs, and laboratory tests up to Week 16. Overall, the total participation time is approximately 20 weeks.

Age: 18Years - 85YearsAll GendersPhase 2
15 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of adding the drug tirzepatide to ongoing ixekizumab therapy in adults with moderate-to-severe plaque psoriasis who are also overweight or obese with at least one weight-related health condition. This Phase 4 study aims to assess how well this combination works in real-world clinical practice over a period of up to 12 months. Participants will continue their prescribed ixekizumab treatment and start taking tirzepatide through subcutaneous injections according to approved guidelines. The study is designed as a single-arm, open-label trial where all participants receive tirzepatide along with ixekizumab. The treatment period covers about one year, during which the response to this combined therapy will be closely observed. Throughout the study, participants will undergo regular assessments to measure improvements in their skin condition and weight. Key outcomes include the percentage achieving minimal impact on quality of life related to dermatology and at least 10% weight loss after 12 months. Additional evaluations at 6 and 12 months will monitor skin involvement, global physician and patient assessments, and weight changes. Safety and tolerability will also be followed during this time.

Age: 18Years +All GendersPhase 4
38 locations
R

Actively Recruiting

Researchers are evaluating whether the drug PF-08046054 works better alone compared to the standard chemotherapy docetaxel in adults with non-small cell lung cancer NSCLC who have tumors expressing PD-L1 at 1% or higher. These participants have cancer that has spread in their body or cannot be removed by surgery or treated with radiation. All participants must have experienced disease progression during or after treatment with PD-L1 or PD-1 inhibitors, platinum-based chemotherapy, and targeted therapies if they have specific genetic mutations. Participants are randomly assigned to one of two groups. One group receives PF-08046054 through an intravenous IV infusion twice every 21-day cycle, while the other group receives docetaxel as an IV infusion once every 21 days. The study may last up to 5 years if the participants cancer responds to treatment. This phase 3 study compares the two therapies to understand their impact on survival and disease progression. During the study, participants will visit the clinic regularly to monitor their health and response to treatment. Researchers will measure overall survival and other outcomes such as progression-free survival, response rates, duration of response, and quality of life using questionnaires. Safety will also be monitored through adverse event evaluations. The study includes biomarker analysis using tumor tissue samples and tracks drug levels and immune responses over time.

Age: 18Years +All GendersPhase 3
447 locations
S

Actively Recruiting

Researchers are evaluating the safety and effects of tilrekimig, a study medicine being tested for severe asthma. The trial focuses on people who have had severe asthma for at least 12 months and experienced two or more asthma attacks in the past year. This phase 3 study aims to understand how tilrekimig compares to placebo shots in improving asthma symptoms and reducing attack rates. Participants will receive either tilrekimig or a placebo through subcutaneous injections administered at the study clinic. The study uses a randomized, double-blind design with parallel groups to compare outcomes. Treatment and observation take place over a 52-week period, with additional monitoring of safety up to 64 weeks. During the study, participants will have regular assessments including lung function tests, symptom questionnaires, and monitoring for asthma exacerbations and safety events. Researchers will measure the annual rate of asthma attacks, lung function changes, quality of life, and other asthma control indicators. The total duration for participant involvement is up to 64 weeks, including follow-up for adverse events.

Age: 12Years - 80YearsAll GendersPhase 3
16 locations
E

Actively Recruiting

This research aims to evaluate the effectiveness and safety of an investigational eye drop solution called Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free, compared to a placebo vehicle solution in adults experiencing eye redness due to minor irritations. The study targets adults with ocular redness and focuses on measuring changes in redness after treatment. It is a Phase 3, randomized, double-blind clinical trial sponsored by Alcon Research. Participants will receive a single dose of the study treatment, one drop in each eye on Day 1. The study includes two groups one receiving the investigational Apraclonidine solution and the other receiving a vehicle placebo. The treatment is given during an in-office visit, and eye redness is assessed before and after instillation at specific timepoints on Day 1 and Day 2. Participants are expected to attend three in-office visits over about one week. Assessments include investigator-rated redness scores at baseline and at several times after treatment, including 1 minute, 15 minutes, 14 hours, and 16 hours post-instillation. Safety and efficacy are monitored through these evaluations. The total study period covers from treatment through follow-up assessments, concluding around one week after the first dose.

Age: 18Years +All GendersPhase 3
9 locations
P

Actively Recruiting

Researchers are evaluating TL-925, an eye drop formulation, for its potential to treat seasonal allergic conjunctivitis using the conjunctival allergen challenge model. This Phase 2, randomized, double-masked, vehicle-controlled study aims to assess the safety and efficacy of TL-925 compared to a placebo in adults with documented ocular allergies. The study is sponsored by Telios Pharma, Inc. and involves about 60 eligible participants. Participants will be randomly assigned in equal numbers to receive either TL-925 or a placebo eye drop. Both treatments will be administered bilaterally as topical ophthalmic eye drops in a clinical setting. The study includes a screening phase followed by a treatment period where the allergic conjunctivitis response will be evaluated using controlled allergen exposure. Throughout the study, participants will be dosed in the clinic, and researchers will monitor ocular itching and conjunctival redness at specific time points after allergen challenge. The primary outcomes focus on itching measured at 3, 5, and 7 minutes and redness at 7, 15, and 20 minutes post-challenge. The total participation duration is aligned with the screening and treatment phases ending by February 2026, with careful safety and efficacy assessments conducted during this time.

Age: 18Years +All GendersPhase 2
1 location
M

Actively Recruiting

Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.

Age: 18Years +All Genders
2393 locations
O

Actively Recruiting

Researchers are conducting an observational study to track the natural history, clinical course, and management patterns of people with limbal stem cell deficiency LSCD. The study focuses on participants aged 12 to 99 years who have a diagnosis of LSCD. It aims to understand how this condition progresses over time by assessing changes in vision and eye structure without administering any study treatments. Participants will not receive any study drug or product as this is a non-interventional study. Instead, researchers will observe and collect information on the conditions progression and management. The study will follow participants from screening through 84 weeks, monitoring various vision-related and anatomical changes that are associated with LSCD. During the study, participants will undergo regular assessments including patient-reported outcomes and multiple vision tests such as photophobic best corrected visual acuity BCVA, low-luminance BCVA, low-contrast BCVA, and contrast sensitivity. Anatomical changes will also be evaluated through eye examinations over the 84-week period. Researchers will track both functional and structural changes to better understand LSCDs impact and progression in the study population.

Age: 12Years - 99YearsAll Genders
8 locations

1-10 of 19

1